Cost-utility of Two Minimally-invasive Surgical Techniques for Operable Oropharyngeal Cancer: Transoral Robotic Surgery Versus Transoral Laser Microsurgery

Enea Parimbelli
University of Pavia

Federico Soldati
Centre Hospitalier Universitaire Vaudois (CHUV), Université de Lausanne (UNIL)

Lorry Duchoud
Centre Hospitalier Universitaire Vaudois (CHUV), Université de Lausanne (UNIL)

John de Almeida
Princess Margaret Cancer Centre

Martina Broglie
University Hospital of Zurich

Silvana Quaglini
University of Pavia

Christian Simon (Christian.Simon@chuv.ch)
Centre Hospitalier Universitaire Vaudois (CHUV), Université de Lausanne (UNIL)

Gian Luca Armas
Centre Hospitalier Universitaire Vaudois (CHUV), Université de Lausanne (UNIL)

Research Article

Keywords: Cost-utility, transoral laser microsurgery, transoral robotic surgery, head and neck cancer, oropharyngeal cancer

DOI: https://doi.org/10.21203/rs.3.rs-574396/v1

License: ☒ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background:

In the past few decades, a re-evaluation of treatment paradigms of head and neck cancers with a desire to spare patients the treatment-related toxicities of open surgery, has led to the development of new minimally invasive surgical techniques to improve outcomes. Besides Transoral Laser Microsurgery (TLM), a new robotic surgical technique namely Transoral Robotic Surgery (TORS) emerged for the first time as one of the two most prominent and widely used minimally invasive surgical approaches particularly for the treatment of oropharyngeal cancer, a sub-entity of head and neck cancers. Recent population-level data suggest equivalent tumor control, but different total costs, and need for adjuvant chemoradiation. A comparative analysis of these two techniques is therefore warranted from the cost-utility (C/U) point of view.

Methods:

Decision-analytical model for comparing TORS and TLM from the cost-utility (C/U) point of view.

Results:

In the base case analysis TLM dominates TORS. This advantage remains robust, even if the costs for TORS reduce by up to 25%. TORS begins to dominate TLM, if less than 59.7% patients require adjuvant treatment, whereby in an interval between 55%-62% cost effectiveness of TORS is sensitive to the prescription of adjuvant CRT. Exceeding 29% of TLM patients requiring a revision of surgical margins renders TORS more cost-effective.

Conclusion:

Non-robotic endoscopic surgery (TLM) is more cost-effective than robotic endoscopic surgery (TORS) for the treatment of oropharyngeal cancers. However, this advantage is sensitive to various parameters, i.e. to the number of re-operations and adjuvant treatment.

Background

In the past few decades, a re-evaluation of treatment paradigms of head and neck cancers with a desire to spare patients the treatment-related toxicities of open surgery, has led to the development of new minimally invasive surgical techniques to improve outcomes. Besides Transoral Laser Microsurgery (TLM), a new robotic surgical technique namely Transoral Robotic Surgery (TORS) emerged for the first time as one of the two most prominent and widely used minimally invasive surgical approaches particularly for the treatment of oropharyngeal cancer, a sub-entity of head and neck cancers[1–3].

TORS is a technique that utilizes wristed robotic surgical technology through a transoral approach in order to facilitate en-bloc resection of tumors. Resections are performed using electrocautery with endoscopes providing different angles of visualization. This technique provides excellent visualization of the disease and possibility to resect the tumor in one piece allowing for more precision in terms of margin analysis[4].
TLM, on the other hand, utilizes lasers, and visualization through laryngoscopes and mouth gags for exposure. Typically, the field of vision is smaller than with TORS, thus the laryngoscopes have to be repositioned several times during the intervention. TLM follows the philosophy of resecting the tumor in pieces. This may confer a better control over the deep margin as a consequence of traversing the tumor and assessing the different cauterisation characteristics between tumor and normal tissue, it may add however a certain degree of uncertainty to the final reading of the margins[5].

A recent population-level analysis demonstrated equivalent survival and similar positive margin rates with both techniques, but a significantly higher rate of post-operative chemoradiation in the TLM group suggesting that uncertainties over margins may lead treating physicians to rather favour the more aggressive postoperative treatment[6].

TLM appears to have a steeper learning curve than TORS. This is of importance to head and neck cancer programs wanting to implement one or the other technique. To the contrary, TLM infers fewer total costs as a consequence of the high equipment and disposable costs incurred during robotic surgery[7].

In summary, a comparative analysis of the two minimally-invasive techniques is warranted for which we used a decision-analytic model for comparing TORS and TLM from the cost-utility (C/U) point of view. Despite TLM and TORS have been independently compared to non-surgical treatment for head and neck cancers [8–14], to the best of our knowledge, there is no literature directly comparing TORS and TLM.

● Materials And Methods

Our base case consists of a Swiss patient with an oropharyngeal squamous cell carcinoma (OPSCC), age 55, with operable T-category (T1 or T2) OPSCC and a probability of regional disease (N+) between 60–70%. Our analyses are performed from a Swiss hospital payer perspective and with a lifetime horizon.

We developed a two-stage model based on (i) a published model about the economic evaluation of TORS vs radiotherapy[13], (ii) additional literature[6] and (iii) authors’ expertise and statistics from the Centre Hospitalier XXX and University Hospital XXX.

The first-stage decision tree accounts for short-term outcomes of the surgery and its complications which are, in turn, carried forward as initial conditions for a second-stage model representing long-term outcomes through a Markov process.

The first-stage decision tree accounts for short-term outcomes of the surgery and its complications which are, in turn, carried forward as initial conditions for a second-stage model representing long-term outcomes through a Markov process.

The first-stage model is depicted in Fig. 1. The two surgical strategies constitute alternatives for the first decision node, after which a chance node distinguishes between cases undergoing surgery alone, and cases requiring adjuvant radiotherapy (RT) or chemoradiotherapy (CRT). Finally, potential complications of the surgical interventions and, where appropriate, associated adjuvant (ADJ) therapy are modeled.
The second-stage model deals with long-term outcomes and is constituted by a Markov model (Fig. 1b). It represents patients entering a state of remission after treatment and models their transitions through other possible health states until death. The Markov cycle has been set to 3 months and the time horizon is the entire patient life. Initial rewards of each Markov model are carried forward from the results of the first-stage model.

Model parameters representing estimates of probabilities of adjuvant treatment were derived from data published by Li et al. [6], which constitute the largest and most recent published database study with relevant outcome data. Other parameters modeling clinical events such as complication rates and recurrence rates were determined from systematic review of the literature[15]. The hospital admission rate for CRT was set at 75% of patients to be admitted once, and 25% twice. The proportion of patients needing hospital admission for RT was set at 25% only once. Regarding the need for a gastrostomy we considered a PEG-rate for CRT of 70% while 20% for RT as per institutional data from CHUV and USZ.

Transition probabilities between different health states of the Markov models were directly adopted from de Almeida et al. [13] and no relevant difference in survival is assumed between the TORS and TLM arms of the model, based on a recent retrospective analysis of the National Cancer Data Base (NCDB) [6]. Table 1, probabilities of events section, reports the specific value used for each parameter. Risk of death from non-cancer-specific causes is modeled following Swiss life tables, acquired through the Swiss office federal de la statistique. In order to perform probabilistic sensitivity analysis (PSA) all parameters were represented using probability distributions. Probabilities of event occurrence were represented as beta distributions, as indicated for variables ranging from 0 to 1 [16] (Table 1).

Costs were directly acquired from the “Centre hospitalier XXX” and “University hospital XXX” administrative departments. Having adopted a hospital perspective, costs incurred by the patient are not considered in our analyses. All costs are represented as Gamma distributions, as suggested by Huinink et al [16] for values greater or equal than 0 (Table 1).

Utility coefficients (UCs) for the health states included in the model were collected with Standard Gamble method through our UceWeb [17, 18] platform from a set of 41 Swiss healthy volunteers. 17 different scenarios were evaluated by each participant [19]. Rating Scale method was also administered, to familiarize participants with the tool and as a consistency check of the obtained values. As for probabilities, UCs are represented as beta distributions (Table 1).

| Table 1 |
| --- |
| Model parameters: Probabilities of occurrence of events, costs and utilities. |
| Variable name | Description                                                                 | Mean   | Standard deviation | Distribution type | Parameter 1 (alpha) | Parameter 2 (beta) |
|---------------|-------------------------------------------------------------------------------|--------|--------------------|-------------------|---------------------|-------------------|
| pes           | Probability of esophageal stenosis                                            | 0.0476 | 0.0005             | Beta              | 4                  | 80                |
| phem          | Probability of hemorrhage                                                     | 0.0243 | 0.0001             | Beta              | 6                  | 241               |
| pho_adj       | Probability of hospital readmission after adjuvant                            | 0.1731 | 0.0027             | Beta              | 9                  | 43                |
| pho_s         | Probability of hospital readmission (TORS or TLM)                            | 0.0333 | 0.0010             | Beta              | 1                  | 29                |
| plg           | Probability of long-term gastrostomy (1 year) after adjuvant treatment        | 0.0500 | 0.0003             | Beta              | 9                  | 171               |
| plt           | Probability of long-term tracheostomy (1 year)                               | 0.0226 | 0.0001             | Beta              | 4                  | 173               |
| psg           | Probability of short-term (6 months) gastrostomy (TORS or TLM)                | 0.0144 | 0.0001             | Beta              | 2                  | 137               |
| psg_adj       | Probability of short-term (6 months) gastrostomy after adjuvant               | 0.2991 | 0.0019             | Beta              | 32                 | 75                |
| por           | Probability of osteoradionecrosis                                             | 0.0265 | 0.0002             | Beta              | 4                  | 147               |
| pff           | Probability of pharyngocutaneous fistula                                      | 0.0253 | 0.0001             | Beta              | 10                 | 385               |
| pTLMAlone     | Probability of TLM alone                                                      | 0.4085 | 0.0007             | Beta              | 134                | 194               |
| pTorsAlone    | Probability of TORS alone                                                     | 0.3740 | 0.0001             | Beta              | 824                | 1379              |
| pCRT_TLM      | Probability of adjuvant CRT (TLM)                                            | 0.6289 | 0.0012             | Beta              | 122                | 72                |
| pCRT_tors     | Probability of adjuvant CRT (TORS)                                           | 0.5272 | 0.0002             | Beta              | 727                | 652               |
|                      | Probability of adjuvant RT (TLM) | Probability of adjuvant RT (TORS) | Probability of local or regional recurrence (first 2 years) | Probability of regional recurrence (first 2 years) | Probability of distant recurrence (first 2 years) | Costs (CHF) |
|----------------------|----------------------------------|-----------------------------------|-------------------------------------------------------------|---------------------------------------------------|--------------------------------------------------|--------------|
| $p_{RT\_TLM}$       | 0.3711                           | 0.0012                            | Beta 72                                                    | Beta 11                                           | Beta 11                                           |              |
| $p_{RT\_tors}$      | 0.4728                           | 0.0002                            | Beta 652                                                   | Beta 11                                           | Beta 11                                           |              |
| $plr^*$              | 0.0064                           | 0.0000                            | Beta 11                                                    | Beta 11                                           | Beta 11                                           |              |
| $prr^*$              | 0.0064                           | 0.0000                            | Beta 11                                                    | Beta 11                                           | Beta 11                                           |              |
| $pdr^*$              | 0.0038                           | 0.0000                            | Beta 11                                                    | Beta 11                                           | Beta 11                                           |              |
| Costs (CHF)          |                                  |                                   |                                                             |                                                   |                                                   |              |
| $c_{TORS}$           | Cost of TORS                      | 14739                             | 869.31                                                     | Gamma 287.4635                                    | 0.0195                                           |              |
| $c_{TLM}$            | Cost of TLM                       | 12671                             | 516.23                                                     | Gamma 602.4698                                    | 0.0475                                           |              |
| $c_{CRT}$            | Cost of adjuvant CRT              | 33911                             | 2079.08                                                    | Gamma 266.0350                                    | 0.0078                                           |              |
| $c_{RT}$             | Cost of adjuvant RT               | 27962                             | 1714.35                                                    | Gamma 266.0342                                    | 0.0095                                           |              |
| $c_{ES}$             | Cost of esophageal stenosis       | 2362                              | 410.65                                                     | Gamma 33.0832                                     | 0.0140                                           |              |
| $c_{GAST}$           | Cost of gastrostomy               | 4332                              | 410.65                                                     | Gamma 111.2820                                    | 0.0257                                           |              |
| $c_{HR\_adj}$       | Cost of hospital readmission (for adjuvant) | 10097                              | 619.05                                                     | Gamma 266.0342                                    | 0.0263                                           |              |
| $c_{HR\_s}$         | Cost of hospital readmission (TORS or TLM) | 8203                              | 803.41                                                     | Gamma 104.2498                                    | 0.0127                                           |              |
| $c_{ORN}$            | Cost of osteoradionecrosis        | 32111                             | 1077.71                                                    | Gamma 887.7769                                    | 0.0276                                           |              |
| $c_{PF}$             | Cost of pharyngocutaneous fistula | 82892                             | 333.96                                                     | Gamma 61609.3654                                   | 0.7432                                           |              |
| $c_{PH}$             | Cost of hemorrhage (from surgical site) | 4469                              | 415.50                                                     | Gamma 115.6865                                    | 0.0259                                           |              |
| $c_{TRACH}$          | Cost of tracheostomy              | 11688                             | 612.67                                                     | Gamma 363.9366                                    | 0.0311                                           |              |
| $c_{REM}$            | Cost of remission 0-2 y           | 168.5                             | 9.68                                                       | Gamma 303.2588                                    | 1.7998                                           |              |
| $c_{2REM}$           | Cost of remission 2-6 y           | 60                                | 9.68                                                       | Gamma 38.4518                                     | 0.6409                                           |              |
|   |   |   |   |   |   |
|---|---|---|---|---|---|
|   |   |   |   |   |   |
| **5 y** |   |   |   |   |   |
| **cPC** | Cost of palliative care | 4137 | 367.86 | Gamma | 126.4754 | 0.0306 |
| **cRR** | Cost of regional recurrence | 7047 | 464.24 | Gamma | 230.4227 | 0.0327 |
| **cLR_chemorad** | Cost of local recurrence (chemoradiation) | 34041 | 2079.08 | Gamma | 268.0786 | 0.0079 |
| **cLR_s** | Cost of local recurrence (surgical resection) | 40513 | 2050.27 | Gamma | 390.4511 | 0.0096 |
| **cDM** | Cost of distant metastasis | 4137 | 367.86 | Gamma | 126.4754 | 0.0306 |
| **cPanendo** | Cost of panendoscopy | 388 | 23.79 | Gamma | 266.0337 | 0.6857 |
| **Utilities** |   |   |   |   |   |
| **uSURG** | Utility coefficient of TORS or TLM | 0.902 | 0.203 | Beta | 1.0328 | 0.1122 |
| **uRT** | Utility coefficient of adjuvant RT | 0.850 | 0.275 | Beta | 0.5831 | 0.1029 |
| **uCRT** | Utility coefficient of adjuvant CRT | 0.794 | 0.317 | Beta | 0.4984 | 0.1293 |
| **uHR** | Utility coefficient of hospital readmission | 0.954 | 0.140 | Beta | 1.1820 | 0.0570 |
| **uPF** | Utility coefficient of pharyngocutaneous fistula | 0.932 | 0.194 | Beta | 0.6374 | 0.0465 |
| **uPH** | Utility coefficient of postoperative hemorrhage | 0.910 | 0.203 | Beta | 0.8986 | 0.0889 |
| **Ug** | Utility coefficient of gastrostomy | 0.916 | 0.209 | Beta | 0.6975 | 0.0640 |
| **Ult** | Utility coefficient of long-term tracheostomy | 0.852 | 0.271 | Beta | 0.6109 | 0.1061 |
| **ues** | Utility coefficient of esophageal stenosis | 0.826 | 0.284 | Beta | 0.6459 | 0.1361 |
| **uORN** | Utility coefficient of osteoradionecrosis | 0.791 | 0.302 | Beta | 0.6428 | 0.1698 |
| **urem** | Utility coefficient of remission after | 0.980 | 0.099 | Beta | 0.7702 | 0.0346 |
surgery and adjuvant

| Parameter       | Description                                                                 | Beta   | SE   |
|-----------------|-----------------------------------------------------------------------------|--------|------|
| uremonlysurg    | Utility coefficient of remission after TORS or TLM alone                    | 0.957  | 0.151|
| ureg            | Utility coefficient of regional recurrence                                 | 0.859  | 0.283|
| ulocxrt         | Utility coefficient of local recurrence, RT                                 | 0.771  | 0.302|
| uloc            | Utility coefficient of local recurrence, requiring surgery                  | 0.755  | 0.316|
| udist           | Utility coefficient of distant recurrence                                   | 0.213  | 0.336|
| upall           | Utility coefficient of palliative care                                      | 0.307  | 0.350|

*NOTE: for prr, plr and pdr 80% of recurrences were modeled in the first 2 years, and the remaining 20% between 2 and 5 years posttreatment (probabilities were adjusted accordingly, assuming 5% of patients have recurrences in the first 2 years*°

Willingness-to-pay was set to 4000 CHF/QALM (i.e. 48000 CHF/QALY [20, 21]. Incremental cost was computed from the difference in expected cost (CHF) between TORS and TLM. Similarly, incremental utility was computed from the difference in expected utility between TORS and TLM. The incremental cost-utility ratio was derived taking the quotient between incremental cost and incremental utility. All cost-utility analyses were performed using TreeAge Pro 2019 software (Williamstown, MA, 2019).

Key model parameters were varied using one-way and two-way deterministic sensitivity analysis in order to assess their impact on the results. In particular, we explored the key role of adjuvant therapy (RT or CRT) after surgery and costs of treatment. Furthermore, all parameters affected by uncertainty were varied in probabilistic sensitivity analysis (PSA). Probabilistic sampling was performed from the distributions described above for probabilities (Beta), costs (Gamma) and utilities (Beta). PSA was performed using second-order Monte-Carlo simulations using 1000 simulations. Incremental cost and effectiveness were plotted with 95% confidence ellipsoids.

### Results

The base case analysis used model parameters presented in the methods section and Table 1. It shows that TORS is moderately more effective than TLM (Months: 342.72 versus 342.62) but also more costly than TLM (Costs in CHF 56879.13 versus 53518.28). When taking into account quality of life, TLM dominates TORS with slightly higher QALMs (216.40 versus 216.31) at a lower cost.

An important role is assumed by the adoption of adjuvant (chemo)radiotherapy after TORS and TLM. Univariate sensitivity analyses on effectiveness show that when the probability of adjuvant therapy is less than 1-0.403 (< 0.597) for TORS, TORS is the optimal option. The same is true for TLM when the probability
of adjuvant therapy is less than 1-0.38 (<0.62). When varied simultaneously in a 2-way sensitivity analysis the effect on the optimal strategy is also evident, as the modality with a lower chance of needing adjuvant treatment is preferred by the model (Fig. 2).

In the hypothetical scenario where improvements to TORS, or careful patient selection, vary the proportion of patients needing adjuvant therapy (i.e. pTorsAlone varies) also the type of the adjuvant treatment begins to play a role. Decreasing the proportion of patients that receive chemoradiotherapy, instead of radiotherapy, as adjuvant treatment after TORS can also make TORS a preferred option over TLM. A 2-way sensitivity analysis on pCRT_Tors and pTorsAlone shows that if the use of adjuvant therapy is lower than 1-0.55 (<0.45), then TORS is the preferred option. However, if the use of adjuvant therapy after TORS is between 0.55–0.62 (pTorsAlone is in the [0.38–0.45] interval) the proportion of patients receiving CRT as adjuvant therapy has to stay under a certain value for TORS to be the optimal alternative (Fig. 3).

A 2-way sensitivity analysis (Fig. 3) shows how being able to decrease the proportion of patients that receive chemoradiotherapy, instead of radiotherapy alone, can make TORS a preferred option over TLM. It shows how the combination of values of pCRT_TORS and pCRT_TLM that sees TORS the preferred option is rather small.

Given that during TLM the tumor is resected in multiple pieces [22, 23], it is common in clinical practice to bring back patients for one or multiple resections in order to achieve negative margins [24]. Our analysis shows that as soon as TLM needs to be repeated once in more than 29% of the patients (krepeatTLM > = 2, threshold value = 1.292 in sensitivity analysis), the increased cost compared to TORS makes TORS the preferred option with a higher net monetary benefit (Fig. 4). On the other hand, results of the base case analysis are rather robust to changes in cost of TORS, confirming TLM as the optimal option even for a relevant (~24%) decrease in TORS cost. A 2-way sensitivity analysis highlights, how repeating TLM even only once (krepeatTLM = 2) and keeping TORS cost as-is, results in TORS being the preferred option for cost-effectiveness (Fig. 4).

Using base-case parameters, PSA shows the majority of simulations favoring TLM, having lower cost (incremental cost is > 0 for most simulations) and close to 0 incremental effectiveness compared to TORS. In the 1000 simulations, with a willingness to pay of 4000 CHF/QALM (i.e. 48000 CHF/QALY), TORS dominates in only 1.1% of the cases, is cost-effective in 5.2%, while TLM is cost-effective in 66% of the cases, and dominates in the remaining 27.7% (Fig. 5).

● Discussion

Our two-stage model-based analysis shows that TLM is currently a cost-effective surgical treatment choice for operable OPSCC. Results, albeit robust, are sensitive to a variability in the proportion and nature of adjuvant therapy and need of performing TLM re-resections impacting costs.

TORS becomes more cost-effective than TLM, if the rate of post-operative adjuvant treatment is below 59.7% and is sensitive to the replacement of RT by CRT in an interval of a rate of adjuvant treatment between 55% and 62%. Higher rates of postoperative therapy after TORS reduce its overall utility and suggest that a careful
case selection, limiting cases needing adjuvant chemoradiotherapy, might be important to impact its cost-effectiveness.

The potential need to repeat TLM surgery for close or positive margins, even only once, results in a significant change in TLM costs, favoring TORS as the cost-effective alternative. According to our one-way sensitivity analysis on costs of TLM (Fig. 4) the threshold for TORS to be more cost-effective as TLM based on the number of re-interventions is found to be at 1.29, suggesting that if 29% or more patients require re-resections after TLM and given that none of the TORS patients’ need to be taken back to the OR outside the regular setting used for the base case scenario, TORS is superior in terms of cost-effectiveness. This percentage is already reached in certain centers even with large experience according to current literature. In a study comprising of 1467 patients treated with TLM for cancers of the oral cavity, oropharynx, larynx, and hypopharynx, 386 patients (26.3%) were taken back for a second resection, and of those even another 22 for a third and a fourth resection with TLM [24]. It seems therefore critical to avoid second operations with TLM by eventually relying more on the use of frozen sections whenever and wherever feasible.

In general, advantages of TORS are the learning curve, allowing for easier adaptation of the surgeon and better results in a shorter amount of time [25, 26]. A clear disadvantage are the upfront capital costs that are widely exceeding the costs of TLM [7]. TLM to the contrary has lower upfront costs, but is technically more challenging requiring more training and a longer time until mastering the procedure [25].

There are certainly limitations of this type of analysis. Modeling is based on various parameter estimates, most of which are retrospectively taken from various sources. Also, this analysis has been performed from a Swiss hospital perspective. It is probable that other healthcare systems account for other costs eventually limiting the generalizability of the results.

The data presented in this study may suggest that TLM is superior with respect to C/U to TORS. However, the decision making on implementing a TORS or TLM program should be based on additional objectives, i.e. the use of a robotic platform for i.e. endoscopic thyroid and neck surgery and/or other applications of the robot. While TLM is based on a technology platform less easy to expand, TORS uses technology for which new applications are easier to identify.

In summary, in this study we provide evidence for an advantage of TLM over TORS in terms of cost-effectiveness for the surgical minimally invasive treatment of operable OPSCCs. However, this advantage is sensitive to the rate of adjuvant treatment, the prescription of RT versus CRT, and the rate of patients requiring re-resections for inadequate margins.

● Declarations

Ethics approval and consent to participate:

All methods were carried out in accordance with relevant guidelines and regulations. This study was an observational, retrospective study that did not jeopardize patient’s clinical management and/or identity.
Therefore, ethical committee approval and signature of informed consent to participate were both waived by the ethics committee of the Canton de Vaud, Suisse.

**Consent for publication:**

All authors approved the final version of this manuscript

**Availability of data and materials:**

The datasets generated during and analyzed during the current study are not publicly available due to hospital policies but are available from the corresponding author on reasonable request.

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests:**

CS reports grants from Roche, grants from Intuitive, personal fees from Pfizer, personal fees from MERCK, personal fees from MSD, personal fees from Seattle Genetics, outside the submitted work.

FS, LD, GLA, JdA, SQ, EP, MB report no competing interests.

**Funding:**

None

**Authors' contributions:**

E.A., F.S., J.dA., S.Q., C.S. wrote the manuscript. E.A., FS., S.Q., C.S. prepared the figures. E.A., S.Q., J.dA., C.S. developed the concept and analyzed the data. E.A., S.Q. performed the mathematical modeling. F.S., L.D., G A., M.B., gathered the clinical and cost data.

**Acknowledgements:**

None

**References**

1. Holsinger FC, Ferris RL: Transoral Endoscopic Head and Neck Surgery and Its Role Within the Multidisciplinary Treatment Paradigm of Oropharynx Cancer: Robotics, Lasers, and Clinical Trials. *J Clin Oncol* 2015, 33(29):3285-3292.
2. Holsinger FC, Sweeney AD, Jantharapattana K, Salem A, Weber RS, Chung WY, Lewis CM, Grant DG: The emergence of endoscopic head and neck surgery. Current oncology reports 2010, **12**(3):216-222.

3. Morisod B, Venara V, II, Alzuphar S, Monnier Y, Bongiovanni M, Hagmann P, Bouchaab H, Bourhis J, Simon C: Minimizing adjuvant treatment after transoral robotic surgery through surgical margin revision and exclusion of radiographic extracapsular extension: A Prospective observational cohort study. Head & neck 2017.

4. Weinstein GS, Quon H, Newman HJ, Chalian JA, Malloy K, Lin A, Desai A, Livolsi VA, Montone KT, Cohen KR et al: Transoral robotic surgery alone for oropharyngeal cancer: an analysis of local control. Archives of otolaryngology–head & neck surgery 2012, **138**(7):628-634.

5. Gorphe P, Simon C: A systematic review and meta-analysis of margins in transoral surgery for oropharyngeal carcinoma. Oral oncology 2019, **98**:69-77.

6. Li H, Torabi SJ, Park HS, Yarbrough WG, Mehra S, Choi R, Judson BL: Clinical value of transoral robotic surgery: Nationwide results from the first 5 years of adoption. The Laryngoscope 2018.

7. Dombree M, Crott R, Lawson G, Janne P, Castiaux A, Krug B: Cost comparison of open approach, transoral laser microsurgery and transoral robotic surgery for partial and total laryngectomies. Eur Arch Otorhinolaryngol 2014.

8. Parimbelli E, Wilk S, Cornet R, Sniatala P, Sniatala K, Glaser SLC, Fraterman I, Boekhout AH, Ottaviano M, Peleg M: A Review of AI and Data Science Support for Cancer Management. medRxiv 2021:2020.2008.20170191.

9. Prettyjohns M, Winter S, Kerawala C, Paleri V: Transoral laser microsurgery versus radiation therapy in the management of T1 and T2 laryngeal glottic carcinoma: which modality is cost-effective within the UK? Clin Otolaryngol 2017, **42**(2):404-415.

10. Spellman J, Coulter M, Kawatkar A, Calzada G: Comparative cost of transoral robotic surgery and radiotherapy (IMRT) in early stage tonsil cancer. American journal of otolaryngology 2020:102409.

11. Rodin D, Caulley L, Burger E, Kim J, Johnson-Obaseki S, Palma D, Louie AV, Hansen A, O’Sullivan B: Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. International journal of radiation oncology, biology, physics 2017, **97**(4):709-717.

12. Sher DJ, Fidler MJ, Tishler RB, Stenson K, Al-Khudari S: Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral Robotic Surgery for Human Papillomavirus-Associated, Clinical N2 Oropharyngeal Cancer. International journal of radiation oncology, biology, physics 2016, **94**(3):512-522.

13. de Almeida JR, Moskowitz AJ, Miles BA, Goldstein DP, Teng MS, Sikora AG, Gupta V, Posner M, Genden EM: Cost-effectiveness of transoral robotic surgery versus (chemo)radiotherapy for early T classification oropharyngeal carcinoma: A cost-utility analysis. Head & neck 2016, **38**(4):589-600.

14. Rudmik L, An W, Livingstone D, Matthews W, Seikaly H, Scrimger R, Marshall D: Making a case for high-volume robotic surgery centers: A cost-effectiveness analysis of transoral robotic surgery. J Surg Oncol 2015.

15. de Almeida JR, Byrd JK, Wu R, Stucken CL, Duvvuri U, Goldstein DP, Miles BA, Teng MS, Gupta V, Genden EM: A systematic review of transoral robotic surgery and radiotherapy for early oropharynx cancer: a
systematic review. *The Laryngoscope* 2014, 124(9):2096-2102.

16. Hunink MGM, Weinstein MC, Wittenberg E, Drummond MF, Pliskin JS, Wong JB, Glasziou PP: *Decision Making in Health and Medicine: Integrating Evidence and Values*, 2 edn. Cambridge: Cambridge University Press; 2014.

17. Salvi E, Parimbelli E, Quaglini S, Sacchi L: *Eliciting and Exploiting Utility Coefficients in an Integrated Environment for Shared Decision-Making*. *Methods of information in medicine* 2019, 58(1):24-30.

18. Parimbelli E, Sacchi L, Rubrichi S, Mazzanti A, Quaglini S: *UceWeb: a web-based collaborative tool for collecting and sharing quality of life data*. *Methods of information in medicine* 2015, 54(2):156-163.

19. Parimbelli E, Simon C, Soldati F, Duchoud L, Armas GL, de Almeida J, Quaglini S: *Quality of life and health-related utility after head&neck cancer surgery*. *medRxiv* 2021:2021.2001.2008.20249019.

20. Ademi Z, Pfeil AM, Hancock E, Trueman D, Haroun RH, Deschaseaux C, Schwenkglenks M: *Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction*. *Swiss medical weekly* 2017, 147:w14533.

21. Pletscher M, Plessow R, Eichler K, Wieser S: *Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland*. *Swiss medical weekly* 2013, 143:w13732.

22. Steiner W, Ambrosch P, Hess CF, Kron M: *Organ preservation by transoral laser microsurgery in piriform sinus carcinoma*. *Otolaryngol Head Neck Surg* 2001, 124(1):58-67.

23. Iro H, Waldfahrer F, Altendorf-Hofmann A, Weidenbecher M, Sauer R, Steiner W: *Transoral laser surgery of supraglottic cancer: follow-up of 141 patients*. *Archives of otolaryngology–head & neck surgery* 1998, 124(11):1245-1250.

24. Jackel MC, Ambrosch P, Martin A, Steiner W: *Impact of re-resection for inadequate margins on the prognosis of upper aerodigestive tract cancer treated by laser microsurgery*. *The Laryngoscope* 2007, 117(2):350-356.

25. Bernal-Sprekelsen M, Blanch JL, Caballero-Borrego M, Vilaseca I: *The learning curve in transoral laser microsurgery for malignant tumors of the larynx and hypopharynx: parameters for a levelled surgical approach*. *Eur Arch Otorhinolaryngol* 2013, 270(2):623-628.

26. Lawson G, Matar N, Remacle M, Jamart J, Bachy V: *Transoral robotic surgery for the management of head and neck tumors: learning curve*. *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies* 2011, 268(12):1795-1801.

**Figures**
Figure 1

short-term outcomes decision tree (a) and second-stage Markov model (b).
Figure 2

1-way and 2-way sensitivity analyses of probability of TORS alone and probability of TLM alone.
Figure 4

1 way sensitivity analysis on cost of TLM (based on number of re-resections needed for negative margins), cost of TORS, and 2-way sensitivity analysis combining the two. Note: NMB = WTP*QALMs.
Figure 5

PSA, base case analysis.